Clinical Trial

Expanded Access Program for CT1812 (Zervimesine)

No Longer Available
View on ClinicalTrials.gov →
Summary
This is a multi-center, open label, expanded access program (EAP) that will provide 100 mg CT1812 for up to one year to participants with mild-to-moderate DLB.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2025-04-29; most recent amendment 2026-05-26.
Status change: Available → No Longer Available 2025-11-18
Status change: Temporarily Not Available → Available 2025-06-09
Status change: Available → Temporarily Not Available 2025-05-14
Trial Details
NCT Number NCT06961760
Lead Sponsor Cognition Therapeutics
Conditions Dementia With Lewy Bodies
Updated on ClinicalTrials.gov 2026-05-28